Introduction a-Linolenic acid (aLNA; 18: 3n-3) is an essential fatty acid in the human diet and is the most abundant n-3 PUFA in the Western diet. The present review will focus on two main areas of the biology of aLNA in human adults; its metabolism and its effect on CVD and inflammation.
The major dietary sources of aLNA are green leaves, and oils used in cooking such as rapeseed oil and soyabean oil where it accounts for up to 10 % of total fatty acids. Flaxseed (also known as linseed) oil, which is commonly consumed as a dietary supplement, is particularly rich in aLNA (. 50 % total fatty acids). Typical consumption of aLNA in Europe, Australia and North America ranges from 0·6 to 1·7 g/d in men and from 0·5 to 1·4 g/d in women (Ministry of Agriculture, Fisheries & Food, 1997; Hulshof et al. 1999; Ollis et al. 1999; Kris-Etherton et al. 2000; Innis & Elias, 2003) .
aLNA can be converted to longer-chain n-3 PUFA such as EPA (20 : 5n-5) and , and it is difficult to distinguish any function which is innate to aLNA from those of its longer-chain metabolites (Sinclair et al. 2000) . The concentration of aLNA in phospholipids in plasma and in cell membranes is typically less than 0·5 % of total fatty acids (Table 1) . It thus seems unlikely that the amount of aLNA present in these pools would be able to exert a significant effect on the biophysical properties of the phospholipid membrane and so influence biological function. Typical consumption of aLNA in Western countries is about 25-and 15-fold greater than of EPA and DHA (Ministry of Agriculture, Fisheries & Food, 1997; Hulshof et al. 1999; Ollis et al. 1999; Astorg et al. 2004) . Conversely, the concentrations of the longer-chain metabolites EPA, docosapentaenoic acid (DPA; 22 : 5n-3) and DHA exceed that of aLNA in most tissues (Table 1) . This apparent mismatch between dietary intakes and concentrations in plasma and tissue lipids supports the view that the primary biological role of aLNA is as a substrate for EPA and DHA synthesis.
Human essential fatty acid deficiency is very rare and the evidence to support the essentiality of aLNA in the human diet is largely restricted to patients who received parenteral feeds. Of patients receiving long-term total parenteral nutrition lacking aLNA, 50 % of children and 30 % of adults exhibited visual dysfunction (Vinton et al. 1990 ). The DHA content of neural membrane phospholipids modulates the activities of several signalling pathways in the brain (Sinclair et al. 2000; Astorg et al. 2004) and is critical for optimal retinal function (Jeffrey et al. 2001; Mitchell et al. 2003) . Thus these findings are consistent with the suggestion that lack of aLNA intake decreased availability of DHA for incorporation into neural membranes (Vinton et al. 1990 ). This conclusion is supported by the observation that the offspring of monkeys fed an n-3 PUFA-deficient diet during pregnancy show visual impairments (Neuringer et al. 1986) and that supplementation of the infant monkeys with aLNA resulted in an increase in the concentration of DHA in neural tissues and an improvement in visual function (Connor & Neuringer, 1988 ).
Patterns of a-linolenic acid consumption in different nations
While typical intakes of aLNA are generally regarded as being approximately 1·5 g/d in Western populations, detailed comparison of the consumption of aLNA shows an almost 3-fold variation between individual nations ( Fig. 1 (A) ). For example, aLNA intake for French men is about one-third that of North American men ( Fig. 1 (A) ). Calculation of the linoleic acid (LA; 18 : 2n-6):aLNA ratio in the diet also shows marked variation between nations. For example, in men the LA:aLNA ratio differs between 5·5 in Denmark and 13·8 in France ( Fig. 1 (B) ). For women, this ratio varies between 4·3 in Denmark and 13·6 in France. However, the LA:aLNA ratio for Spanish men and women together is 27·0 ( Fig. 1 (B) ). The importance of these variations in the LA:aLNA ratio in the diet is that the relative consumption of LA and aLNA modulates the extent to which aLNA is converted to long-chain metabolites. This will be discussed in more detail later. One potential implication is that recommendations for the intakes of n-3 and n-6 PUFA may need to be devised for individual nations according to their habitual LA and aLNA consumption.
Bioavailability of a-linolenic acid from the diet
The bioavailability of aLNA from the diet is determined by the efficiency of absorption across the gastrointestinal tract. There is very little information regarding the absorption of aLNA by the human gut. Measurement of the concentrations of 2 H-labelled fatty acids in the triacylglycerol (TAG) fraction of chylomicrons following ingestion in a single meal showed that the absorption and secretion of oleic acid (18 : 1n-9), LA and aLNA were similar (Emken et al. 1994) . Although this does not specifically measure absorption across the gut, it does indicate that the overall bioavailability of aLNA from a meal is similar to that of other unsaturated fatty acids. Direct assessment of absorption of aLNA requires measurement of the output in stool compared with consumption of a known amount in a meal. To date there have been no published data from such an experiment. Measurement of the cumulative concentration of labelled aLNA in stool collected over 5 d following ingestion of 750 mg [U-13 C]aLNA by a single individual showed that greater than 96 % of the administered dose was absorbed (GC Burdge, unpublished results) . Similar levels of aLNA uptake have also been reported in patients with ileostomies who were fed 100 g linseed oil (Saunders & Sillery, 1988) . These findings suggest that absorption of aLNA across the gut and its secretion into the bloodstream is efficient in man. a-Linolenic acid and health-related outcomesa-Linolenic acid metabolism in man aLNA which has been absorbed by the gut passes into the circulation primarily esterified to TAG carried by chylomicron particles and so is made available for uptake by tissues and incorporation into pools destined for storage, cell membranes, production of energy, mobilisation and conversion to longer-chain PUFA. The metabolic fates of aLNA in man are summarised in Fig. 2 .
Incorporation of a-linolenic acid into adipose tissue
Adipose tissue accounts for approximately 15 % of body mass in men and 23 % of body mass in women. Thus incorporation of aLNA into this storage pool represents a potentially important route of disposal of dietary aLNA and a reserve pool which is available for mobilisation during periods of increased demands. aLNA accounts for about 0·7 % of total fatty acids in neutral lipids in adipose tissue in men and women, while DHA concentration is approximately 0·1 % and EPA is practically undetectable (Tang et al. 1993; Kaminskas et al. 1999) . Thus, it can be calculated that, in a 75 kg man with a fat mass of 15 %, the whole body aLNA reserve in adipose tissue would be approximately 79 g (roughly equivalent to typical intake over 53 d). Likewise, in a 65 kg woman with a fat mass of 23 %, the whole body aLNA reserve in adipose tissue would be approximately 105 g (roughly equivalent to typical intake over 70 d). It is conceivable that such reserves may buffer variations in dietary intake and so prevent development of deficiency of aLNA or of longer-chain metabolites. During the postprandial period there is a metabolic drive to store fatty acids which is facilitated by the insulindependent increase in lipoprotein lipase activity and of fatty acid uptake in adipose tissue. In the fasting state, plasma NEFA are derived primarily from the release of adipose tissue TAG stores by the action of hormone-sensitive lipase. The exchange of aLNA between the blood and adipose tissue compartments has not been characterised in detail in human subjects in vivo. However, when men consumed [U-
13 C]aLNA, labelled aLNA was detected in the plasma NEFA pool within 2 h and reached a peak at 6 h . One interpretation is that during the early postprandial period labelled aLNA detected in the NEFA pool probably reflects incomplete entrapment of fatty acids released by the hydrolysis of chylomicron TAG (Evans et al. 2002) . At later time points (for example, about 6 h) the presence of labelled aLNA in plasma NEFA may reflect recently assimilated fatty acids. Overall, the rapid release of aLNA into the NEFA pool, together with the aLNA pool associated with chylomicron remnant particles, would tend to facilitate supply of aLNA to the liver. The concentration of [
13 C]aLNA in plasma NEFA was 2-fold greater in women than in men over 21 d . This suggests sex differences in the metabolism of aLNA in storage pools and potentially greater short-term availability of aLNA for supply to the liver in women.
Comparison of the metabolic fates of EPA and DHA during the postprandial period showed enrichment of DHA in the plasma NEFA pool, presumably as a result of incomplete entrapment of fatty acids released by hydrolysis of chylomicron TAG, compared with EPA (Heath et al. 2003) . Furthermore, there was greater incorporation of DHA than of EPA into VLDL TAG. This suggests differential uptake of PUFA released by lipoprotein lipase activity which appears to facilitate supply of DHA to the liver and remobilisation on VLDL.
b-Oxidation of a-linolenic acid
Since aLNA is essential in the human diet and is consumed in relatively modest amounts, it is somewhat surprising that it is a substrate for b-oxidation and energy production. However, the appearance of 13 C as 13 CO 2 on breath following the ingestion of 13 C-labelled aLNA has been clearly demonstrated in a number of studies and the area under the time £ enrichment curve has been used to estimate the proportion of ingested aLNA used for energy production. The values produced by such calculations probably represent an approximately 30 % underestimate of the actual proportion of ingested aLNA used in energy production due to trapping of 13 CO 2 in bicarbonate pools (Irving et al. 1983) . Since the period of collection of CO 2 differs between reports from 9 to 48 h, the estimates of partitioning towards b-oxidation differ from 15 to 33 % (DeLany et al. 2000; Vermunt et al. 2000; Bretillon et al. 2001; McCloy et al. 2004) . When subjects were studied over 24 h under comparable conditions, the fractional b-oxidation of aLNA in women was estimated as approximately 22 % of administered dose compared with 33 % in men . This may reflect lower muscle mass in women, and the potential overall effect would be to increase the proportion of ingested aLNA available for conversion to longer-chain PUFA in women compared with men. The extent of partitioning of aLNA towards b-oxidation, when assessed under identical conditions, was almost twice that of palmitic, stearic and oleic acids, and greater than LA (DeLany et al. 2000) (Fig. 3 (A) ). This may reflect the higher affinity of carnitine palmitoyl transferase-1 for aLNA (Clouet et al. 1989) .
One study has reported the effect of altering the n-3 PUFA content of the background diet on the proportion of ingested [ 13 C]aLNA recovered as 13 CO 2 on breath . Three groups of men matched for BMI, age and fasting plasma TAG concentrations consumed a standard meal containing 700 mg [U-
13 C]aLNA and excretion of 13 CO 2 on breath was measured over 24 h. Subjects then consumed either a control diet (aLNA 1·7 g/d, EPA þ DHA 0·4 g/d), a diet containing an increased amount of aLNA
for 8 weeks. There was no difference in energy intake between the groups. The proportion of ingested labelled aLNA recovered as 13 CO 2 on breath was then measured again. There was no significant difference between baseline and the end of the 8-week intervention period in the proportion of labelled aLNA partitioned towards b-oxidation in the group consuming the control, increased aLNA or increased EPA þ DHA diets ( Fig. 3  (B) ). This suggests that the extent of partitioning of aLNA towards b-oxidation is relatively stable over short periods of time and that altering the amount of either aLNA or longchain n-3 PUFA in the diet does not significantly alter this process.
Recycling of carbon from a-linolenic acid into saturated and monounsaturated fatty acids
In addition to conversion to CO 2 by the activity of Kreb's cycle, carbon in acetyl-CoA generated by fatty acid b-oxidation may be recycled and used in fatty acid synthesis de novo. This process has been suggested to be important as a source of fatty acids in pregnant and fetal monkeys (Sheaff-Greiner et al. 1996) and rats (Cunnane et al. 1994 (Cunnane et al. , 2003 . There is one report which describes recycling of carbon released by b-oxidation of aLNA in human subjects . Men (35 years of age) and women (28 years of age) consumed 700 mg [U-13 C]aLNA and the concentrations of labelled saturated fatty acids (SFA) and MUFA in plasma were measured over 21 d. Labelled palmitic, stearic, palmitoleic and oleic acids were detected in plasma phosphatidylcholine (PC) and TAG, but not other plasma lipid pools in both men and women. The proportion of label was 6-fold greater in plasma PC compared with TAG in men and 25-fold greater in plasma PC than TAG in women. These data suggest preferential channelling of SFA and MUFA synthesised by the recycling pathway into phospholipids by the liver, which is in contrast to the molecular partitioning of the bulk of the hepatic SFA and MUFA pools towards TAG. Since typical daily consumption of aLNA in the UK is 25-fold and 15-fold greater than EPA and DHA, respectively (Ministry of Agriculture, Fisheries & Food, 1997) , it seems unlikely that recycling of carbon from aLNA simply represents a means of disposal of excess aLNA not required for EPA and DHA synthesis.
The total concentration of labelled SFA and MUFA in plasma lipids was 20 % greater in men compared with women (Table 2 ). This is in agreement with greater partitioning of aLNA towards b-oxidation in men compared with women . Comparison of the amount of 13 C recycled into SFA and MUFA with that incorporated by desaturation and elongation of aLNA into longer-chain PUFA in plasma over 21 d showed marked differences between men and women ( Table 2 ). In men, the carbon recycling greatly exceeded conversion to longer-chain PUFA. In contrast, the amount of carbon recycled into SFA and MUFA in women was about 20 % of that recovered in n-3 PUFA (Table 2) . One overall implication of these findings is that the extent of partitioning of aLNA towards b-oxidation and carbon recycling may be an important control point in the regulation of the availability of aLNA for conversion to longer-chain PUFA and that the relative partitioning between these metabolic fates differs markedly between men and women. This suggests that the extent of partitioning of aLNA towards b-oxidation may not simply reflect sex differences in muscle mass.
The general pathway for conversion of a-linolenic acid to longer-chain polyunsaturated fatty acids A pathway for the conversion of the essential fatty acids LA and aLNA to longer-chain PUFA has been described in rat liver (for a review, see Sprecher, 2002) and is summarised in Fig. 4 . All reactions occur in the endoplasmic reticulum with the exception of the final reaction which results in the formation of DHA. Since both n-6 and n-3 PUFA are metabolised by the same desaturation -elongation pathway, there exists potential for competition between these two families of fatty acids. The initial conversion of aLNA to 18 : 4n-3 by the action of D6-desaturase is the rate-limiting reaction of the pathway. The affinity of D6-desaturase for aLNA is greater than for LA (Sprecher, 2002) . However, the typically higher concentration of LA than aLNA in cellular pools results in greater conversion of n-6 PUFA. The introduction of a double bond at the D6 position is followed by the addition of 2C by elongase activity and then by desaturation at the D5 position by D5-desaturase to form EPA. DPA is synthesised from EPA by the addition of 2C. The conversion of DPA to DHA has been a matter of controversy and two pathways have been suggested for this reaction. First, D4-desaturase activity has been suggested to be the primary mechanism for DHA synthesis (Infante & Huszagh, 1998) . However, others have demonstrated that the synthesis of DHA involves the formation of 24-carbon intermediates, a second desaturation at the D6 position and limited peroxisomal b-oxidation (Sprecher, 2002) . Studies in which subcellular organelles were isolated and then recombined and reports of the action of the specific D6-desaturase inhibitor SC-26 196 (Harmon et al. 2003) strongly support the second pathway. Furthermore, patients with peroxisome disorders such as Zellweger's syndrome have lower plasma DHA concentration, which is the result of a failure to convert DPA to DHA in the absence of an active peroxisomal b-oxidation pathway (Martinez, 2000) . Thus the consensus pathway for the conversion of DPA to DHA is as follows: DPA is elongated to 24 : 5n-3 which is desaturated at the D6-position by the action of D6-desaturase activity to form 24 : 6n-3. It is unclear whether the same enzyme is responsible for desaturation of aLNA and 24 : 5n-3 (Marzo et al. 1996; de Antueno et al. 2001; D'andrea et al. 2002) . Then 24 : 6n-3 is translocated from the endoplasmic reticulum to the peroxisome where the acyl chain is shorted by 2C by one cycle of the boxidation pathway to form DHA. DHA is then translocated back to the endoplasmic reticulum. Although the precise regulation of the translocation steps and limited b-oxidation is not known, it is possible that this represents a locus for metabolic regulation that facilitates the control of DHA synthesis independently from the preceding steps of the pathway.
The activity of the desaturation -elongation pathway in the liver is the most important in terms of supply of aLNA metabolites to other tissues. However, expression of D6 and D5 desaturases has also been reported in human heart, brain, placenta, skeletal muscle, kidney, and pancreas (Cho et al. 1999 ). An active desaturation -elongation pathway has also been reported in immortalised human T cells (Jurkat cells), but not B cells (Marzo et al. 1995) , and in sebaceous glands (Ge et al. 2003) . Human epidermis appears to possess D6-desaturase, but not D5-desaturase activity (Chapkin et al. 1986) . Whether the activity of the desaturation -elongation pathway contributes quantitatively to meeting the demands of these tissues for long-chain PUFA remains to be determined.
a-Linolenic acid conversion to longer-chain n-3 polyunsaturated fatty acids in human adults
Current understanding of the extent to which man can convert aLNA to longer-chain PUFA is based on the findings of studies reporting the outcomes of chronic increases in intake of aLNA on concentrations of n-3 PUFA in plasma, cell and tissue lipid pools, and of shorter-term studies in which subjects consume a bolus of aLNA labelled with a stable isotope.
Effects of chronically increased a-linolenic acid consumption
A number of studies have reported the effects of consuming increased amounts of aLNA, usually via consumption of oils with a high aLNA content or of products made with those oils (for example, spreads), on the fatty acid composition of plasma or cell lipids (Tables 3 and 4) . These studies were conducted either in men or in mixed a-Linolenic acid and health-related outcomes Table 3 . DPA, docosapentaenoic acid; M, male; F, female; PC, phosphatidylcholine; NA, data not available; PL, phospholipid; CE, cholesteryl ester; TAG, triacylglycerol. *Mean values were significantly different from baseline (P , 0·05). †aLNA intake refers to total intake unless otherwise specified. ‡Approximate intake. §Excluding background diet contribution of approximately 1 g/d. Table 4 . Studies investigating the effect of increased a-linolenic acid (aLNA) consumption on the fatty acid composition of circulating cells in human subjects groups of men and women, used intakes of aLNA ranging from less than 1 to 20 g/d, and were of a few weeks' to many months' duration (Tables 3 and 4 ). Despite differences in the study design, physical form in which the aLNA was presented and the duration of the studies, overall they consistently demonstrate increased proportions of EPA in both plasma and cell lipids when aLNA intake is increased (Tables 3 and 4) . The relationship between increased aLNA intake and increased EPA concentration in plasma phospholipids is a significant linear one (r 0·846; P ¼ 0·004; Fig. 5 ). The relationship for cell phospholipids is also likely to be linear, but there are insufficient data for a single cell type to allow this to be clearly identified at this stage. There is also some variation in the response between studies which might reflect differences in age and sex mix of the subjects studied, differences in the fatty acid content of the background diet, differences in the way in which aLNA was provided and differences in analytical procedures used. Because of competition for metabolism between LA and aLNA, the LA content of the diet may influence conversion of aLNA to longer-chain derivatives. If this is so, then the EPA content of blood and cell lipids should be greater at a given intake of aLNA if LA intake is decreased. A study by Chan et al. (1993) demonstrated that this is indeed the case. Subjects consumed diets providing 7 g aLNA/d for 18 d against a background of either 21 or 50 g LA/d. The proportion of EPA was greater after the low-compared with the high-LA background in plasma PC (0·8 v. 0·3 % of fatty acids), plasma phosphatidylethanolamine (0·9 v. 0·3 % of fatty acids) and platelet PC (0·25 v. 0·1 % of fatty acids).
Several studies also demonstrate increased proportions of DPA in plasma and cell lipids when aLNA consumption is increased (Tables 3 and 4 ). The studies also consistently demonstrate that increased consumption of aLNA does not result in increased proportions of DHA in plasma or cell lipids (Tables 3 and 4) . Indeed many studies report a tendency for DHA to decline when aLNA consumption is markedly increased, although few studies have identified this as a statistically significant effect (Tables 3 and 4) .
Overall, these studies demonstrate that chronically increased consumption of aLNA results in conversion to EPA resulting in increases in EPA concentration in plasma and cell pools, while the extent of conversion to DHA is insufficient to increase the concentration of this fatty acid.
Estimates of a-linolenic acid conversion from stableisotope tracer studies
A number of studies using aLNA labelled with either 13 C or 2 H have provided estimates of the extent of conversion to longer-chain PUFA in man. The advantages and limitations of these techniques have been reviewed (Emken, 2001 ). There remain unresolved issues regarding standardisation of quantification of data (particularly how conversion between fatty acids should be estimated), kinetic modelling, variation between subjects including age and sex, the method of administration of the labelled fatty acid, the duration of the study, the extent to which the background diet is controlled and the use of measurements of labelled fatty acids in blood (including which lipid pool should be measured) as a marker of fatty acid metabolism within tissues. Together these factors have resulted in considerable heterogeneity in the findings of such studies (Emken et al. 1994 (Emken et al. , 1999 Salem et al. 1999; Vermunt et al. 2000; Pawlosky et al. 2001 Pawlosky et al. , 2003a Goyens et al. 2005; Hussein et al. 2005) (Table 5 ). This presents a considerable challenge to any attempt to reach a consensus view on aLNA metabolism in man. Nevertheless, at present there are no practical alternatives to these stable-isotope tracer techniques to study human aLNA metabolism in vivo.
The outcomes of stable-isotope tracer studies designed to investigate conversion of aLNA to longer-chain PUFA in man are summarised in Table 5 . The general consensus of these studies is that the proportion of aLNA entering the desaturation -elongation pathway and converted to EPA and DPA is low. The extent of conversion of aLNA to DHA is even less clear (Table 5 ). The highest estimated fractional conversion is 4 % (Emken et al. 1994) , while most other studies have reported lower estimates of conversion (0·05 % or less) (Emken et al. 1999; Salem et al. 1999; Vermunt et al. 2000; Pawlosky et al. 2001 Pawlosky et al. , 2003a Goyens et al. 2005; Hussein et al. 2005) and one study failed to detect significant incorporation of stable isotope into DHA above background 13 C enrichment . Pawlosky et al. (2001) have suggested estimates for the efficiency of conversion of individual steps in the desaturation -elongation pathway from kinetic analysis based on the concentrations of individual 2 H-labelled fatty acids in plasma from a mixed group of men and women consuming a beef-based diet. The findings of the study were that the efficiency of conversion of aLNA to EPA was 0·2 %, of EPA to DPA 65 % and of DPA to DHA 37 %. Thus, the overall efficiency of conversion from aLNA is 0·2 % to EPA, 0·13 % to DPA and 0·05 % to DHA. This is in general agreement with the other studies summarised in Table 5 and with the assumption that the first reaction catalysed by D6-desaturase is the rate-limiting step of the pathway. Change in the proportion of EPA (%) Fig. 5 . The relationship between consumption of a-linolenic acid (aLNA) and the change in the concentration of EPA in plasma phospholipids. Data are taken from references cited in Table 3 . Several studies have reported the effects of modifications to the background diet on the extent of aLNA conversion to long-chain n-3 PUFA determined using stable-isotope tracers. The effect of increased consumption of EPA þ DHA or DHA alone on this process is of interest because of the potential for feedback inhibition of this pathway. Emken et al. (1999) compared the effect of consuming diets either containing , 0·1 g DHA/d or supplemented with 6·5 g purified DHA/d. There was a 76 % reduction in EPA synthesis and an 88 % reduction in DHA synthesis in the group receiving the DHA supplement. Others have reported a decrease in the conversion efficiency of DPA to DHA following the consumption of a fish-based diet (containing EPA þ DHA) compared with a beef-based diet in a mixed group of men and women (Pawlosky et al. 2003b) . However, when the fractional conversion of DPA to DHA was calculated separately for men and women, the decrease in DHA synthesis as a result of consuming a fish-based diet was only found in the female subjects (Pawlosky et al. 2003a) . Consumption of 1·6 g EPA þ DHA/d for 8 weeks decreased EPA and DPA, but not DHA, synthesis when aLNA conversion was compared before and after the intervention in the same individuals . These studies indicate that increased consumption of longchain n-3 PUFA acts to down regulate their synthesis from aLNA, possibly by activation of peroxisomal proliferatoractivated receptor-a leading to inhibition of D6-desaturase transcription (Tang et al. 2003) . One recent study showed that consuming either 17 g LA/d or 17 g aLNA/d inhibited the conversion of the alternate series of fatty acids (Hussein et al. 2005) . In contrast, Vermunt et al. (2000) found that increased aLNA intake (8 g/d) decreased EPA, DPA and DHA synthesis, although others have not found this .
Overall, substantial increases in the intakes of individual fatty acids are able to modify the conversion of aLNA, although there are inconsistencies in the magnitude of these effects between reports.
Since there is a positive linear relationship between the amount of aLNA consumed and the change in plasma phospholipid EPA concentration (Fig. 5) , it is possible to evaluate the accuracy of the estimates of aLNA conversion provided by studies using stable-isotope tracers. It is assumed that doubling the provision of EPA will increase its concentration in plasma phospholipid by 100 %. The daily intake of EPA in the UK is about 0·06 g (Ministry of Agriculture, Fisheries & Food, 1997) . Thus a further 0·06 g would be required to double the concentration of EPA in the circulation. In order to make a direct comparison between pools, estimated fractional conversion of aLNA based upon the measurement of 13 C incorporation into plasma phospholipid will be used, which is about 5 % in men . In the UK, where this study was conducted, men consume about 1·5 g aLNA/d. Partitioning towards b-oxidation removes about 33 % of aLNA from the pool derived from the diet which is available for conversion, leaving 1·0 g. As there are no estimates for the fractional partitioning of aLNA into storage or membrane pools it will be assumed that all of the remaining aLNA is available for conversion, which obviously results in an overestimation of the synthesis of EPA. If it is assumed that about 5 % is converted to EPA, then 1 g aLNA will provide 0·05 g EPA, which would almost double the provision of EPA. Thus, the consumption of 1 g of aLNA above the background diet would be expected to double the concentration of EPA in the circulation. Others have suggested that, based on kinetic models, 0·2 % of aLNA is converted to EPA (Pawlosky et al. 2001) , which would provide 0·002 g EPA, which would mean that 300 g aLNA would need to be consumed in order to provide an additional 0·06 g above the intake in the background diet. The data in Fig. 5 show that 5 g is required to double the provision of EPA, and so neither of these estimates of aLNA conversion based upon stable-isotope tracer studies is entirely correct. There are two possible explanations. First, the true level of conversion lies between the two experimental values and is in the order of 2 % if it is assumed that 1·7 g (i.e. 33 % of 5 g) is lost in b-oxidation and all of the remaining aLNA is available for desaturation and elongation. This is unlikely to be true. Second, if the estimate of 5 % conversion was correct, then the pool available for conversion must be less than 1 g by a factor of 5. One possible explanation is that 80 % of aLNA which is ingested and is not used to produce energy enters pools which are not available for conversion to longer-chain PUFA, such as storage pools in adipose tissue or structural pools in cell membranes. If so, the pool of aLNA available for conversion would be 0·2 g for each 1 g consumed. For example, if 5 g aLNA are consumed, b-oxidation would account for 1·7 g, and 2·3 g would enter storage or membrane pools, leaving 1·0 g which would be available for conversion. Of this, 5 % would be used to provide 0·05 g EPA. The proportion of ingested aLNA incorporated into pools not used for conversion or b-oxidation, presumably storage or cell membranes, is comparable with the estimated upper range (57 %) of incorporation of [
13 C]aLNA into total adipose tissue (McCloy et al. 2004) . The calculations presented here are obviously an oversimplification of the processes which determine the extent to which dietary aLNA is converted to EPA. However, these estimates do suggest a level of fractional conversion of aLNA to EPA, which can explain the data from dietary intervention studies, and are consistent with the findings of at least some of the stable-isotope tracer studies.
a-Linolenic acid metabolism: sex differences
The majority of investigations of aLNA metabolism in human subjects have focused on groups of relatively young healthy individuals, either men or mixed groups of men and women. There is relatively little information regarding the effects of sex on this process. Two reports have specifically studied aLNA conversion in women of reproductive age. showed that conversion of aLNA to EPA and DHA in women aged about 28 years was substantially greater (2·5-fold and . 200-fold, respectively) than in a comparable study of men of similar age (Table 5 ). This finding is strongly supported by kinetic analysis, which showed that the rate-constant coefficient for the conversion of DPA to DHA was approximately 4-fold greater in women compared with men (Pawlosky et al. 2003a) (Table 5 ). This may reflect a greater availability of aLNA for conversion in women than a-Linolenic acid and health-related outcomesin men that may perhaps, in part, be due to lower partitioning towards b-oxidation. However, since the rateconstant coefficient for the conversion of DPA to DHA was greater in women than men (Pawlosky et al. 2003a) , it is likely that there is a sex-related difference in the activity of the desaturation -elongation pathway.
One possible explanation for the greater synthesis of EPA and DHA from aLNA in women compared with men is the action of oestrogen. DHA synthesis was almost 3-fold greater in women using an oral contraceptive pill containing 17a-ethylnyloestradiol than in those who did not . The suggestion that oestrogen may increase the activity of the desaturation -elongation pathway is consistent with the finding that oestrogen-based hormone replacement therapy in postmenopausal women resulted in greater plasma dihomo-g-linolenic and arachidonic acid concentrations than before treatment (Ottosson et al. 1984) . Furthermore, DHA concentration in the plasma cholesteryl ester fraction has recently been shown to be greater in women (0·53 % total fatty acids) compared with men (0·48 % total fatty acids) consuming diets controlled for energy and aLNA content, although DHA is a minor component of this plasma lipid pool (Giltay et al. 2004b) . Interestingly, administration of 17a-ethylnyloestradiol to male to female transsexuals increased the concentration of DHA in plasma cholesteryl esters by 42 % which is in agreement with the effects of oral contraceptive pill use on aLNA conversion . Conversely, testosterone decreased DHA concentration by 22 % in female to male transsexuals (Giltay et al. 2004b) . Hormone replacement therapy in postmenopausal women also increased plasma cholesteryl ester arachidonic acid and DHA concentrations (Giltay et al. 2004a) . Our own data (L Bakewell, PC Calder and GC Burdge, unpublished results) show that women (aged 18 to 35 years) have a 50 % higher concentration of DHA in plasma PC compared with men of similar age and BMI (. 20 and , 30 kg/m 2 ) (Fig. 6 ). Together these data strongly support the suggestion that sex hormones, in particular oestrogen, regulate the activity of the desaturation -elongation pathway in man.
One possible biological role for greater capacity for aLNA conversion in women may be in meeting the demands of the fetus and neonate for DHA. The developing human fetus assimilates at least 400 mg DHA per week during the third trimester (Lauritzen et al. 2001) . Since this estimate reflects only brain, adipose tissue and liver requirements, the overall demands for DHA are likely to be substantially greater. Desaturase activities in the developing human liver appear to be lower than in adults (de Gomez Dumm & Brenner, 1975; Sauerwald et al. 1977; Poisson et al. 1993; Salem et al. 1996; Carnielli et al. 1996) , and so the capacity of the fetus and neonate to satisfy their demands for DHA may be limited. Thus, assimilation of DHA by the fetus has to be met primarily by supply of DHA by the mother. In pregnant women, plasma PC DHA concentration increases by approximately 33 % between 16 weeks (170 mmol/l) and 40 weeks (230 mmol/l) gestation (Postle et al. 1995) . When the increase in maternal blood volume during pregnancy is taken into account (Gregersen & Rawson, 1959) , in women there is an overall doubling of DHA in the circulation. Since circulating oestrogen concentration rises during pregnancy due to synthesis and secretion by the placenta, one possibility is that aLNA conversion may increase during gestation. This is supported by studies in rats that indicate that the increased plasma PC DHA concentration during pregnancy is the result of physiological adaptations to hepatic phospholipid (Burdge et al. 1994 ) and aLNA (Larque et al. 2003) metabolism. If true in women, one implication would be that the 50 % variation between pregnant women in plasma PC DHA concentration at term (Postle et al. 1995 ) may reflect differences in aLNA metabolism in addition to any dietary effects. This may influence the supply of DHA to the fetus and, in turn, the development and function of neural tissues.
Consumption of 10·7 g aLNA/d by lactating women increased maternal plasma, erythrocyte and breast-milk aLNA concentration (Francois et al. 2003) . The effect on breast-milk EPA and DPA concentrations is less clear, as the difference between baseline DPA concentration (0·19^0·05 %) and that after 4 weeks of supplementation (0·17^0·02 %) does not support the claim that the DPA content of milk increased over time (Francois et al. 2003) . Increased consumption of aLNA did not alter breast-milk DHA concentration (Francois et al. 2003) . This is consistent with the finding that newly synthesised arachidonic acid is a minor component of the arachidonic acid content of breast milk (Del Prado et al. 2001) . One interpretation is that the incorporation of PUFA into milk may be dependent upon mobilisation of stores accumulated in adipose tissue before conception and during pregnancy. If so, this emphasises the importance of adequate nutrition of women both before and during pregnancy. Furthermore, since prolactin suppresses oestrogen activity, the activity of the desaturationelongation pathway may be down regulated in lactating compared with non-pregnant and pregnant women, and so these results do not exclude the possibility of increased DHA synthesis during pregnancy. 
Conversion of a-linolenic acid to longer-chain polyunsaturated fatty acids: the legacy of our ancestors?
The function of the brain is arguably the major distinguishing characteristic of Homo sapiens. The human brain weighs about 1300 g, of which 60 % is lipid. Longchain PUFA are critically important for neurological development and function, in particular DHA, and deficit in the DHA content of neural membranes is associated with impaired function (Fernstrom, 1999) . Thus the interaction between the availability of long-chain PUFA, in particular DHA, and the development of the brain is likely to have been a critical process in the evolution of H. sapiens. The growth in both size and functional capacity which accompanied the evolution of H. sapiens from our common ancestor with the chimpanzees 5·8 -7·1 million years ago (Hacia, 2001) would have required an increase in the availability of DHA to support the increased synthesis of brain tissues during development and to replenish the turnover of neural membrane phospholipids. The level of DHA in the meat of species living on the African savanna, although greater than domesticated species, is relatively low (Broadhurst et al. 2002) and the hunting skills required too great for this to be a major source of DHA to support the early evolution of the hominid brain (Muskiet et al. 2004 ). An alternative theory of the ancestral hunter -gatherer which emphasises the role of long-chain PUFA in the evolution of the brain suggests that hominids evolved along the margins of lakes and rivers, and along the seashore where fish provided a richer source of DHA than would have been obtained by a hunter-gatherer lifestyle (Broadhurst et al. 2002; Gibbons, 2002a; Muskiet et al. 2004) . This is supported by the relatively large numbers of remains of early hominids and of their tools at Lake Turkana in the East African Rift Valley (now Kenya), in the Southern African Cape and in the Central African Chad Basin (Gibbons, 2002b) . Furthermore, when early humans left Africa, they did so along a coastal route (Macaulay et al. 2005) . One interpretation is that evolution of the human brain may have occurred in the presence of an adequate dietary supply of preformed DHA, and that there was little need for synthesis of DHA from aLNA. Furthermore, experiments in animal models suggest that recycling of DHA in cell membranes of the brain and the retina is highly efficient (Wiegand et al. 1991; Chang et al. 1999) . In rats, 97 % of DHA in the brain is derived from the recycling of DHA from membrane sources (Chang et al. 1999) . If this is also found in human adults, this suggests that the actual daily requirements for DHA to replenish neural membranes may be very small, and so could be provided by relatively low dietary intakes. In the context of the evolution of the brain, such adaptation would tend to buffer its function against variations in the intake of DHA from the diet. The development of the brain represents the period of greatest sensitivity to deficits in supply of DHA. Since desaturase activities in fetal liver are unlikely to satisfy demands for DHA (Salem et al. 1996) , the developing fetal brain is highly dependent upon a supply of preformed DHA from the mother. In this context, the capacity to increase maternal DHA synthesis by the action of oestrogen may be of particular importance in ensuring a supply of DHA to the fetus. Speculatively, this ability may have evolved to protect the developing fetal brain from a deficit in DHA accumulation, a risk which would be substantially greater if supply of DHA from the maternal diet was the sole source of DHA for supply to the fetus. Furthermore, accumulation of DHA into adipose tissue during the third trimester is about 10-fold greater (380 mg/ week) than into the fetal brain (35 mg/week) (Clandinin et al. 1981) . This suggests that one of the reasons why man (Poissonnet et al. 1984) , unlike other primates (Adolph & Heggeness, 1971; Lewis et al. 1983) , has evolved the capacity to accumulate adipose stores in late gestation may be to provide a nutritional buffer during the transition from placental to oral supply (Kuzawa, 1998; Correia et al. 2004) , thus preventing a deficit in DHA. This store is likely to depend upon supply of preformed DHA from the mother.
Overall, the capacity of modern man to convert aLNA to longer-chain PUFA, in particular DHA, appears to be consistent with our evolutionary past and the fatty acid content of our ancestral diet. This is reflected in differences in the efficiency of conversion of aLNA to DHA between men and women. In women, capacity to up regulate may be important for protecting the development of the fetal brain against deficit in DHA accumulation during pregnancy. The contrastingly low level of DHA synthesis in men may reflect the activity of recycling mechanisms that may limit the demands of neural tissue for DHA.
a-Linolenic acid and human health-related outcomes
Long-chain n-3 polyunsaturated fatty acids and human health
Studies of disease incidence in native Inuit populations in Greenland, Canada and Alaska identified less cardiovascular and inflammatory disease than expected (Dyerberg et al. 1978; Kromann & Green, 1980; Bjerregaard & Dyerberg, 1988; Newman et al. 1993) . This has been attributed to the very high dietary intake of long-chain n-3 PUFA among these populations (Bang et al. 1976) . Epidemiological studies in Western Europe, the USA and Japan indicate decreased risk of CVD (for references, see Bucher et al. 2002; Kris-Etherton et al. 2002; Calder, 2004a; He et al. 2004 ) and inflammation (Shoda et al. 1996; Pischon et al. 2003; Lopez-Garcia et al. 2004 ) with increasing habitual consumption of fish, oily fish, or longchain n-3 PUFA. Supplementation studies with long-chain n-3 PUFA, usually as fish oil, have demonstrated beneficial impacts on a multitude of cardiovascular risk factors including fasting TAG concentrations (for reviews, see Harris, 1996; Roche & Gibney, 1999) , postprandial lipaemia (for a review, see Williams, 1997) , blood pressure (for a meta-analysis, see Geleijnse et al. 2002) , platelet aggregation Goodnight et al. 1981; von Schacky et al. 1985) , blood coagulation and fibrinolysis (see British Nutrition Foundation, 1992), heart rate variability (Christensen et al. 1996 (Christensen et al. , 2001 ), cardiac arrhythmias (Schrepf et al. 2004) , vascular reactivity (Chin et al. 1993; McVeigh et al. 1994; Goode et al. 1997; Tagawa et al. 1999) , and inflammation (for reviews, see Calder, 2001 Calder, , 2002 Calder, , 2003 Calder, , 2005 . Paradoxically there are reports that longchain n-3 PUFA increase the susceptibility of LDL to oxidation ex vivo (Suzukawa et al. 1995; Sorensen et al. 1998; Finnegan et al. 2003b) , which, if it occurred in vivo, would be a deleterious, pro-atherogenic effect. Long-chain n-3 PUFA also affect immune function (for reviews, see Calder, 2001; Calder et al. 2002) . If the effects of long-chain n-3 PUFA are representative of general effects of this class of fatty acids, then aLNA too could beneficially affect a range of cardiovascular risk factors and so could lower the risk of CVD in particular, but also inflammatory, and perhaps other, conditions. Alternatively through conversion to its longer-chain, more unsaturated derivatives which are found in fish oil, aLNA could exert the same health benefits ascribed to EPA and DHA. This has become an attractive notion because there are more sources of aLNA (nuts, seeds, vegetable oils) than of long-chain n-3 PUFA; aLNArich oils are readily available, inexpensive and sustainable; aLNA-rich oils are more easily incorporated into existing foodstuffs (spreads, cooking oils, cakes, biscuits, snacks etc) than are fish oils, thus representing less of a challenge to food technologists; and high amounts of aLNA do not affect the taste, smell and shelf life of foodstuffs in the same way that inclusion of high amounts of long-chain n-3 PUFA can and so are more attractive to food producers, food retailers and consumers. In addition, the lower propensity of aLNA to free radical attack, compared with EPA and DHA, means that the risk of increased oxidative damage to lipoproteins such as LDL and to cell membranes is much lower. Finally, the view that the current intake of the n-6 PUFA LA is too high (Simopoulos, 2001; Lands, 2003) and increases the risk of thrombotic, inflammatory and allergic sequelae, provides an opportunity for aLNA to decrease disease risk as a result of being a replacement in the diet for LA. For these reasons there has been significant interest in the effects of dietary aLNA intake on CVD and on its risk factors.
a-Linolenic acid and cardiovascular disease

Epidemiological associations
Several studies report a protective effect of aLNA towards CVD. A population-based case -control study in Costa Rica reported that high adipose tissue aLNA content, a marker for intake, was associated with lower risk of myocardial infarction (Baylin et al. 2003) . Dietary aLNA intake was significantly inversely associated with mortality from CHD in the Multiple Risk Factor Intervention Trial (Dolecek, 1992) . The highest quintile of aLNA intake (1·36 g/d) was associated with 45 % fewer coronary deaths in women compared with the lowest quintile (0·71 g/d) (Hu et al. 1999) . Dietary aLNA intake was inversely associated with risk of myocardial infarction among men (Ascherio et al. 1996) ; there was a relative risk of 0·41 for each 1 % increase in energy intake as aLNA. In a study of over 4400 men and women the highest quintile of aLNA intake (1·1 g/d) was associated with 40 % lower mortality from coronary artery disease compared with the lowest quintile of intake (0·5 g/d) (Djousse et al. 2001) . In addition, dietary aLNA intake was inversely related to carotid atherosclerosis (Djousse et al. 2003) and to calcified atherosclerotic plaque in the coronary arteries (Djousse et al. 2005) . In contrast to these findings, other epidemiological studies found no association between aLNA intake and CHD risk (Simon et al. 1995; Oomen et al. 2001) or mortality (Pietinen et al. 1997; Oomen et al. 2001) .
A recent meta-analysis of five prospective cohort studies (Dolecek, 1992; Ascherio et al. 1996; Pietinen et al. 1997; Hu et al. 1999; Oomen et al. 2001) concluded that high aLNA intake is associated with decreased risk of fatal CHD (Brouwer et al. 2004) .
Intervention studies
The well-known Lyon Heart Study reported a substantial reduction in coronary events and deaths among myocardial infarction survivors following a Mediterranean-style diet which included an aLNA-rich margarine providing 1·5 g aLNA/d (de Lorgeril et al. 1994) . However, this intervention also involved several other dietary changes and so the contribution, if any, of increased aLNA intake to the positive outcomes cannot be identified.
a-Linolenic acid and cardiovascular risk factors
Blood lipids
A number of studies have investigated the effect of increased aLNA consumption on blood cholesterol, LDL and HDL concentrations (Table 6 ). While some of these studies report little effect of aLNA intervention, several indicate that aLNA is similar to LA with respect to blood cholesterol concentration (Kestin et al. 1990; Chan et al. 1991; Mantzioris et al. 1994; Arjmandi et al. 1998; Pang et al. 1998; Sodergren et al. 2001; Bemelmans et al. 2002; Finnegan et al. 2003b; Zhao et al. 2004) . Likewise some of these studies indicate similar effects of aLNA and LA on LDL-and HDL-cholesterol concentrations (Kestin et al. 1990; Chan et al. 1991; Arjmandi et al. 1998; Sodergren et al. 2001; Bemelmans et al. 2002; Finnegan et al. 2003b; Zhao et al. 2004) . However, two studies (Mantzioris et al. 1994; Pang et al. 1998) suggest that aLNA is not as effective as LA in lowering LDL-cholesterol concentrations. Furthermore, studies reporting that aLNA decreased HDL concentration (Nestel et al. 1997; Rallidis et al. 2003) did not see this effect with LA, while Bemelmans et al. (2002) found that HDL concentration was significantly lower (by 4 % or 0·05 mM) after aLNA than after LA. Taken together these data would suggest that, while aLNA is cholesteroland LDL-lowering, it is less effective than LA and that aLNA, unlike LA, may decrease HDL concentration. Studies investigating the effect of aLNA on fasting plasma TAG concentrations are contradictory, with most reporting no change from baseline, several reporting an increase or a tendency to an increase, and two reporting a decrease (for references, see Table 6 ). These differences in outcome may relate to the fat content of the background diet, to habitual dietary fat composition, to whether subjects were placed on a standardised diet before the aLNA intervention, to the amount of aLNA and of other fatty acids supplied, and to the degree of triacylglycerolaemia at baseline. It is interesting that the two studies reporting decreased plasma TAG concentrations used very high aLNA intakes (Singer et al. 1986; Zhao et al. 2004) . Some studies permit the effect of aLNA on fasting TAG Table 6 . Controlled intervention studies in human subjects investigating the effect of a-linolenic 
LDL-cholesterol None concentrations to be directly compared with that of LA. Kestin et al. (1990) , Nestel et al. (1997) , Pang et al. (1998) , Rallidis et al. (2003) and Zhao et al. (2004) found that the effects of a high-aLNA diet were not different from those of an LA-rich diet. However, Arjmandi et al. (1998) and Finnegan et al. (2003b) , who found that aLNA tended to increase TAG concentration, did not see this effect with a high-LA diet, while Bemelmans et al. (2002) reported that plasma TAG concentration was significantly higher (12 % or 0·24 mM) after aLNA than after LA. These studies are suggestive that aLNA has a TAG-raising effect compared with LA.
Postprandial lipaemia
Lichtenstein et al. (1993) reported no differences in the postprandial TAG response to a test meal in subjects who consumed diets rich in rapeseed, maize or olive oils. More recently, Finnegan et al. (2003b) found no effect of diets containing 4·5 or 9 g aLNA/d on the postprandial TAG response to a test meal, compared with study entry or with an LA-rich diet.
Low-density lipoprotein oxidation
Nestel et al. (1997) found that the lag time of Cu-induced oxidation of LDL was significantly lower (by 14 min; about 22 %) after consumption of an aLNA-rich (20 g/d) low-fat (26 % energy from fat) diet compared with a monounsaturated fat-rich low-fat-diet. In addition, the content of thiobarbituric acid reactive substances in the oxidised LDL was higher if the LDL came from subjects on the aLNArich diet (Nestel et al. 1997) . However, Finnegan et al. (2003b) reported no effect of diets containing 4·5 or 9 g aLNA/d on lag time of LDL oxidation, compared with study entry or with an LA-rich diet. Ezaki et al. (1999) found no effect of 4·2 g aLNA/d on plasma lipid peroxide or oxidised LDL concentrations in elderly Japanese subjects.
Blood pressure Berry & Hirsch (1986) noted that a 1 % increase in adipose tissue aLNA content was associated with a 5 mmHg decrease in systolic and diastolic blood pressure. Salonen et al. (1988) reported an inverse association between aLNA consumption and blood pressure in a large prospective study. However, 38 g aLNA/d for 2 weeks did not affect systolic or diastolic blood pressure in normotensive or hypertensive subjects (Singer et al. 1986 ). Likewise, 9·2 g aLNA/d did not affect systolic or diastolic blood pressure in a 6-week intervention study in normotensive hypercholesterolaemic subjects (Kestin et al. 1990) . Furthermore, 6·3 g aLNA/d for 2 years did not affect systolic or diastolic blood pressure in subjects with multiple cardiovascular risk factors (Bemelmans et al. 2002) ; some of these subjects were under antihypertensive therapy.
Vascular reactivity
Nestel et al. (1997) found increased arterial compliance (aortic flow velocity and aortic root driving pressure) after 4 weeks of 20 g aLNA/d (9 % energy) (and 2·7 % energy as LA) in exchange for oleic acid in obese subjects.
Haemostasis and platelet aggregation
Increased consumption of aLNA results in an increased content of EPA and DPA in platelets (see Table 4 ) in parallel with a decreased content of arachidonic acid. This might be expected to affect platelet aggregation, since this is regulated in part by arachidonic acid-and EPA-derived eicosanoids (Needleman et al. 1979; Knapp et al. 1986 ). Indeed, healthy men consuming a high-aLNA diet (8·5 % energy from aLNA; approximately 18 g/d) had decreased collagen-induced platelet aggregation compared with those on an LA-rich diet (12 % energy from LA) (Allman et al. 1995) . Freese et al. (1994) reported a decrease in ADPinduced platelet aggregation in hyperlipaemic subjects consuming 2·1 % energy as aLNA (and 6·5 % energy as LA) compared with a low-aLNA diet (0·3 % energy from aLNA and 8 % energy from LA). However, there are reports that substantially increased consumption of aLNA (3·7, 5·9 or 15·4 g/d) does not affect platelet aggregation induced by collagen (Freese & Mutanen, 1997 , Li et al. 1999 . Furthermore, there was no effect of 6·8 or 10 g aLNA/d on ADP-induced platelet aggregation (Wensing et al. 1999; Junker et al. 2001) . A number of intervention studies report little effect of aLNA on coagulation and fibrinolytic factors, including factor VII, factor XII, fibrinogen, plasminogen activator inhibitor-1 or tissue plasminogen activator concentration or factor VII, plasminogen activator inhibitor-1 or tissue plasminogen activator activity (Table 7) . Intakes of aLNA studied have been in the range of 3·7 to 15·4 g/d (see Table 7 ).
Inflammation
Increased consumption of aLNA results in an increased content of EPA and DPA in the membranes of inflammatory cells such as neutrophils and monocytes (see Table 4 ) in parallel with a decreased content of arachidonic acid. This might be expected to affect inflammation, since this is regulated in part by arachidonic acid-and EPA-derived eicosanoids (see Lewis et al. 1990; Tilley et al. 2001; Calder 2003 Calder , 2004b Calder , 2005 . A recent study reported an inverse association between aLNA intake and plasma concentrations of IL-6 and soluble vascular cell adhesion molecule-1 but not of C-reactive protein (CRP), soluble TNF receptor-2, soluble E-selectin or soluble intercellular adhesion molecule-1 in samples taken from the Nurses' Health Study 1 cohort (Lopez-Garcia et al. 2004) . After adjustment for age, BMI, physical activity, smoking status, alcohol consumption and intakes of LA and SFA, there were significant negative associations between aLNA intake and plasma CRP, IL-6, and soluble E-selectin concentrations (Lopez-Garcia et al. 2004) . These observations would suggest that increasing aLNA intake would result in decreased inflammation. Table 8 summarises intervention studies that have investigated the effect of aLNA on inflammatory outcomes in human subjects; some studies have examined the circulating concentrations of inflammatory markers such as CRP, soluble adhesion molecules or cytokines (Junker et al. 2001; Thies et al. 2001a; Rallidis et al. 2003 Rallidis et al. , 2004 Bemelmans et al. 2004; Zhao et al. 2004) , while other studies have examined inflammatory cell responses ex vivo (Caughey et al. 1996; Healy et al. 2000; Thies et al. 2001a; Kew et al. 2003; Wallace et al. 2003) . Caughey et al. (1996) reported that 13·7 g aLNA/d for 4 weeks resulted in a decrease in ex vivo production of prostaglandin E 2 , TNF-a and IL-1b by endotoxin-stimulated mononuclear cells by 33, 27 and 30 %, respectively. By comparison, fish oil providing 2·7 g EPA þ DHA/d decreased production of these inflammatory mediators by 55, 70 and 78 % respectively (Caughey et al. 1996) . Thus on a g/d basis, long-chain n-3 PUFA are about eight to fourteen times more potent than aLNA with respect to this outcome in healthy subjects. In contrast to the observations of Caughey et al. (1996) , several studies using lower intakes of aLNA (2 to 9·5 g/d) did not find effects on neutrophil chemotaxis, neutrophil respiratory burst, monocyte respiratory burst, TNF-a, IL-1b and IL-6 production by endotoxin-stimulated mononuclear cells, all studied ex vivo, or on soluble adhesion molecule concentrations (for details, see Table 8 ). Furthermore, a study by Rallidis et al. (2004) reported no effect of 8 g aLNA/d on soluble intercellular adhesion molecule-1 or soluble E-selectin concentrations and a similar decrease in soluble vascular cell adhesion molecule-1 concentration in both aLNA and control groups. Likewise, Bemelmans et al. (2004) found no effect of 6·3 g aLNA/d on soluble intercellular adhesion molecule-1 concentration at 1 and 2 years of intervention. Taken together, these data suggest that increasing aLNA intake to . 9 g/d is required in order for marked anti-inflammatory effects to be seen. Even then, the effects will be much more modest than those exerted by long-chain n-3 PUFA (Caughey et al. 1996) . However, both Rallidis et al. (2003) and Bemelmans et al. (2004) did find a significant decrease in CRP concentration, suggesting that this may be a marker that is more sensitive to intakes of aLNA that do not affect soluble adhesion molecule or cytokine concentrations or ex vivo inflammatory cell responses. One study using a very high intake of aLNA (approximately 17·5 g/d) reported significant decreases in both CRP and soluble adhesion molecule concentrations (Zhao et al. 2004) . Interestingly, the authors found that the changes in these inflammatory markers were significantly related to changes in serum concentrations of EPA or EPA þ DPA, but not of aLNA (Zhao et al. 2004) . This suggests that the observed effects are due to the long-chain n-3 PUFA rather than to aLNA per se. Thus the probable explanation for the lack of anti-inflammatory effect of aLNA at modest (Healy et al. 2000; Thies et al. 2001a; Kew et al. 2003; Wallace et al. 2003) , and even at rather high (Kew et al. 2003) , intakes is that there has been insufficient conversion of aLNA to the more active EPA.
a-Linolenic acid and immune function
A limited number of studies have investigated the effect of aLNA on immune functions in human subjects, apart from those with an inflammatory component. Table 9 summarises the studies that exist in this area. These studies have Table 7 . Controlled intervention studies in human subjects investigating the effect of a-linolenic acid (aLNA) on haemostatic factors a-Linolenic acid and health-related outcomes Table 8 . 
M, male; PBMC, peripheral blood mononuclear cells; F, female; CRP, C-reactive protein; sVCAM, soluble vascular cell adhesion molecule; sICAM, soluble intercellular adhesion molecule; sE-selectin, soluble E-selectin; SAA, serum amyloid A.
* aLNA intake refers to total intake unless otherwise specified. † Excluding background diet contribution of approximately 1 g/d. Table 9 . Controlled intervention studies in human subjects investigating the effect of a-linolenic a-Linolenic acid and health-related outcomesinvestigated ex vivo immune cell functions such as phagocytosis of bacteria, lymphocyte proliferation and cytokine production in response to mitogenic stimulation and in vivo responses to antigen challenge (delayed type hypersensitivity response). It is evident that increasing aLNA intake to as much as 9 g/d has no effect on those human immune functions examined in these studies (Table  9) . One study using a very high intake of aLNA (approximately 20 g/d) reported significant decreases in some immune parameters, but not others (Kelley et al. 1991) . T cell proliferation was decreased in response to one mitogen but not others and the significance of this is not clear. However, the observed decreased delayed type hypersensitivity response, which is the summation of the in vivo response to intradermal challenge with seven antigens, is in accordance with decreased T cell function. Thus, very high intakes of aLNA might impair T cellmediated immune responses.
Conclusions
Epidemiological studies show that aLNA intake is inversely associated with risk of CVD. This inverse relationship may explain the benefit on mortality seen in an intervention study that involved increased aLNA intake (de Lorgeril et al. 1994) . Intervention studies are indicative that substantially increased aLNA intake can beneficially affect a range of cardiovascular risk factors including blood cholesterol (Chan et al. 1991; Cunnane et al. 1995; Arjmandi et al. 1998; Junker et al. 2001; Sodergren et al. 2001; Karvonen et al. 2002; Zhao et al. 2004) , LDL-cholesterol (Chan et al. 1991; Cunnane et al. 1995; Arjmandi et al. 1998; Junker et al. 2001; Sodergren et al. 2001; Bemelmans et al. 2002; Karvonen et al. 2002; Zhao et al. 2004) and TAG (Singer et al. 1986; Zhao et al. 2004) concentrations, vascular reactivity (Nestel et al. 1997) , platelet aggregation (Allman et al. 1995) and inflammation (Caughey et al. 1996; Zhao et al. 2004) . However, the effect on cholesterol concentration is similar to that of LA, while aLNA is less potent than LA at decreasing LDL concentration (Mantzioris et al. 1994; Pang et al. 1998) . Furthermore aLNA can decrease HDL concentration (Nestel et al. 1997; Junker et al. 2001; Rallidis et al. 2003 ) which LA does not do and, in contrast to the effects of long-chain n-3 PUFA, may increase TAG concentration. More modest increases in aLNA intake do not affect blood lipid concentrations, postprandial lipaemia, blood pressure, platelet aggregation, haemostatic factors, inflammation or immune function. These effects contrast with those of long-chain n-3 PUFA and it is apparent from studies where aLNA and long-chain n-3 PUFA have been compared that aLNA is substantially less potent (for example, Caughey et al. 1996) . The reason why very high intakes of aLNA may induce qualitatively similar effects to those of long-chain n-3 PUFA (for example, decreasing TAG concentration, platelet aggregation and inflammation), while lower intakes do not, may be that the high intakes allow sufficient synthesis of EPA to occur to induce biologically effective changes in EPA concentration. This is borne out by the observations of Zhao et al. (2004) that the aLNA-induced changes in inflammatory markers were significantly related to changes in serum concentrations of EPA or EPA þ DPA, but not of aLNA. Similar to this, Caughey et al. (1996) related the effects of aLNA on inflammatory cytokine production to the increased content of EPA in mononuclear cells. Thus, the probable explanation for the lack of biological effect of more modest intakes of aLNA is that there has been insufficient conversion of aLNA to the more active EPA. From this point of view increased intake of aLNA offers little real advantage compared with increased intake of long-chain n-3 PUFA, and may even be disadvantageous if aLNA does increase blood TAG concentration. One clear advantage of increased aLNA intake is that it seems unlikely to make LDL more sensitive to oxidation, a process which can be promoted by long-chain n-3 PUFA. Once again, the fact that one study using a very high intake of aLNA reported increased susceptibility of LDL to oxidation (Nestel et al. 1997 ) may reflect the fact that the LDL may have been significantly richer in EPA and DPA as a result of aLNA conversion.
Overall conclusions
Human conversion of aLNA to its longer-chain derivatives, especially DHA, is limited, although conversion is greater in women than men. The limited extent to which aLNA is converted to its longer-chain metabolites may explain, at least in part, the relative lack of effectiveness of increased consumption of aLNA on risk factors for CVD, inflammatory markers, and immune function. Dietary intervention studies with aLNA have been conducted either in men or in mixed groups of men and women, and the effect of increased aLNA intake on health outcomes in young women has not been investigated. Since young women possess greater capacity for conversion to EPA and DHA, it is possible that they may exhibit a greater response in terms of health outcomes to increased dietary intake of aLNA. For example, increased aLNA intake may lead to greater reserves of EPA and DHA in adipose tissue which could be mobilised and supplied to the fetus during pregnancy. Furthermore, increased dietary intake of aLNA by young women may provide a means of ameliorating inflammatory disease symptoms. Thus there is a need for more research investigating the role of aLNA in promoting health in young women. 
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